These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12756028)

  • 1. Bull's eye maculopathy with deferoxamine.
    Bansal V; Elgarbly I; Ghanchi FD; Atkinson PL
    Eur J Haematol; 2003 Jun; 70(6):420-1. PubMed ID: 12756028
    [No Abstract]   [Full Text] [Related]  

  • 2. Results of long term iron chelation treatment with deferoxamine.
    Davis BA; Porter JB
    Adv Exp Med Biol; 2002; 509():91-125. PubMed ID: 12572991
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of oral iron chelator L1.
    Hershko C
    Lancet; 1993 Apr; 341(8852):1088-9. PubMed ID: 8096975
    [No Abstract]   [Full Text] [Related]  

  • 4. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine related maculopathy: a case report.
    Arora A; Wren S; Gregory Evans K
    Am J Hematol; 2004 Aug; 76(4):386-8. PubMed ID: 15282675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of iron chelation therapy with deferoxamine.
    Cohen A
    Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bull's-Eye Maculopathy with Deferoxamine Treatment].
    Schmidt D; Finke J
    Klin Monbl Augenheilkd; 2004 Mar; 221(3):204-9. PubMed ID: 15052528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalassemia: Yesterday, Today, Tomorrow.
    Hadjidemetriou M
    Am J Hematol; 2017 Jun; 92(6):490-492. PubMed ID: 28370242
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ; Weatherall DJ
    Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal imaging in a case of deferoxamine-induced maculopathy.
    Gelman R; Kiss S; Tsang SH
    Retin Cases Brief Rep; 2014; 8(4):306-9. PubMed ID: 25372534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
    Efendieva EG; Dashkova NG
    Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.